HC Wainwright Reiterates Buy Rating for Innate Pharma (NASDAQ:IPHA)

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $11.50 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 385.23% from the company’s current price.

Separately, Citigroup cut their price target on Innate Pharma from $12.00 to $8.00 in a report on Monday, September 18th.

Innate Pharma Trading Down 3.7 %

Innate Pharma stock opened at $2.37 on Wednesday. Innate Pharma has a 52 week low of $1.81 and a 52 week high of $3.97. The business’s 50-day simple moving average is $2.55 and its 200-day simple moving average is $2.85.

Institutional Investors Weigh In On Innate Pharma

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after acquiring an additional 108,335 shares in the last quarter. Jane Street Group LLC lifted its position in Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock worth $127,000 after purchasing an additional 23,012 shares during the period. Balyasny Asset Management LLC acquired a new stake in Innate Pharma during the third quarter worth $32,000. Millennium Management LLC boosted its stake in Innate Pharma by 389.8% during the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock worth $267,000 after buying an additional 57,050 shares in the last quarter. Finally, Optiver Holding B.V. increased its holdings in Innate Pharma by 112.3% in the 1st quarter. Optiver Holding B.V. now owns 224,097 shares of the company’s stock valued at $636,000 after buying an additional 118,563 shares during the period. Institutional investors own 0.29% of the company’s stock.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.